Controlled Trial of High Doses of Pemoline for Adults With Attention-Deficit/Hyperactivity Disorder
The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Abstract
Despite the increasing awareness of attention-deficit/hyperactivity disorder (ADHD) in adults, there are a limited number of controlled pharmacologic studies of this disorder. Because the stimulant medication magnesium pemoline (Cylert, Abbott Laboratories, Abbott Park, IL) has been found effective in treating ADHD in pediatric groups, we tested its efficacy in adults with ADHD using higher daily doses than those previously studied. We conducted a 10-week, double-blind, placebo-controlled, crossover design study of pemoline at a target daily dose of 3 mg/kg per day in 35 adult patients with DSM-III-R and -IV ADHD. We used standardized structured psychiatric instruments for diagnosis. To measure improvement, we used separate assessments of ADHD, depressive, and anxiety symptoms at baseline and at each biweekly visit. ADHD outcome was determined using the ADHD symptom checklist and Clinical Global Impression scales of Severity and Improvement. Of the 35 adults with ADHD who were randomized in the trial, 27 (77%) completed the protocol. Treatment with pemoline in the final week of the 4-week active phase was best tolerated at doses substantially lower than the target dose of 3 mg/kg per day (mean dose, 2.2 mg/kg per day; mean+/-SD, 148+/-95 mg). Pemoline was significantly better at reducing ADHD symptoms compared with placebo (z = 2.4,p < 0.02). Using a predefined 30% reduction in symptoms as an indication of improvement, 50% of pemoline-treated subjects and 17% of subjects in the placebo group were considered positive responders (chi2 = 7.1, p = 0.008). These results indicate that pemoline is moderately effective in the treatment of ADHD in adults. Although robust doses were targeted, most adults preferred more moderate dosing (120-160 mg/day). Given the limited efficacy, tolerability, and concerns of hepatic dysfunction, pemoline should be considered as second-line medication for treating ADHD in adults.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.6.885 · Cited by 1,421
Hyperactive Boys Almost Grown Up: I. Psychiatric Status
Gittelman, R. (1985) · Archives of General Psychiatry · doi:10.1001/archpsyc.1985.01790330017002 · Cited by 977
(1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.12.1792 · Cited by 950
Self-citationWEISS, G., HECHTMAN, L., MILROY, T., & PERLMAN, T. (1985) · Journal of the American Academy of Child Psychiatry · doi:10.1016/s0002-7138(09)60450-7 · Cited by 753
BIEDERMAN, J., FARAONE, S., MILBERGER, S., CURTIS, S., CHEN, L., MARRS, A., OUELLETTE, C., MOORE, P., & SPENCER, T. (1996) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-199603000-00016 · Cited by 510
Self-citationSpencer, T. (1995) · Archives of General Psychiatry · doi:10.1001/archpsyc.1995.03950180020004 · Cited by 402
Self-citationWender, P. H. (1981) · Archives of General Psychiatry · doi:10.1001/archpsyc.1981.01780290083009 · Cited by 337
(1996) · American Journal of Psychiatry · doi:10.1176/ajp.153.9.1147 · Cited by 228
Self-citation
Cited by
Attention-deficit/hyperactivity disorder in adults: an overview
Faraone, S. V., Biederman, J., Spencer, T., Wilens, T., Seidman, L. J., Mick, E., & Doyle, A. E. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(00)00889-1 · Cited by 679
Self-citationDiagnostic Controversies in Adult Attention Deficit Hyperactivity Disorder
McGough, J. J., & Barkley, R. A. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.11.1948 · Cited by 388
Spencer, T., Biederman, J., Wilens, T., Doyle, R., Surman, C., Prince, J., Mick, E., Aleardi, M., Herzig, K., & Faraone, S. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.043 · Cited by 385
Self-citationA Controlled Clinical Trial of Bupropion for Attention Deficit Hyperactivity Disorder in Adults
Wilens, T. E., Spencer, T. J., Biederman, J., Girard, K., Doyle, R., Prince, J., Polisner, D., Solhkhah, R., Comeau, S., Monuteaux, M. C., et al. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.2.282 · Cited by 272
Self-citationNutt, D. J., Fone, K., Asherson, P., Bramble, D., Hill, P., Matthews, K., Morris, K. A., Santosh, P., Sonuga-Barke, E., Taylor, E., et al. (2007) · Journal of Psychopharmacology · doi:10.1177/0269881106073219 · Cited by 259
“…et al., 1989; Paterson et al., 1999; Taylor and Russo, 2000, 2001 Ib), Adderall mixed amfetamine salts (Spencer et al., 2001; Biederman et al., 2005 Ib), the psychostimulant pemoline (Wilens et al., 1999b Ib), and the dopaminergic agent bupropion (Wender and Reimherr, 1990; Wilens et al., 2001 Ib).”
Background
Metadata
- Authors
- Wilens, T. E., Biederman, J., Spencer, T. J., Frazier, J., Prince, J., Bostic, J., Rater, M., Soriano, J., Hatch, M., Sienna, M., Millstein, R. B., & Abrantes, A.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1999-06
- Volume
- 19
- Issue
- 3
- Pages
- 257-264
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W1979465426
- Cited by
- 65
- References
- 8
- FWCI
- 5.48
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Controlled Trial of High Doses of Pemoline for Adults With Attention-Deficit/Hyperactivity Disorder. https://app.cochat.ai/papers/10.1097/00004714-199906000-00009
- The paper
- Wilens, T. E., Biederman, J., Spencer, T. J., Frazier, J., Prince, J., Bostic, J., Rater, M., Soriano, J., Hatch, M., Sienna, M., Millstein, R. B., & Abrantes, A. (1999). Controlled Trial of High Doses of Pemoline for Adults With Attention-Deficit/Hyperactivity Disorder. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199906000-00009
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.